Canada: U.S. Supreme Court Holds Medical Diagnostic Process Patent Ineligible For Claiming Unpatentable Laws Of Nature

Last Updated: April 30 2012
Article by Peter S.L. Wong

On March 20, 2012, the United States Supreme Court decided Mayo Collaborative Services v. Prometheus Laboratories, Inc., No. 10-1150 (Prometheus), unanimously holding that a particular medical diagnostic process claimed was ineligible for patent protection.

More broadly, Prometheus provides the Court's latest guidance on the boundary between patent-eligible process claims and patent-ineligible natural laws, physical phenomena and abstract ideas.

Prometheus was the exclusive licensee of two patents1 containing claims generally directed to a method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder comprising two steps: (a) administering one of a class of drugs (thiopurines) and (b) determining the level of a specified metabolite, wherein a level below a specified lower threshold indicates a need to increase the amount of the drug subsequently administered, and a level above a specified upper threshold indicates a need to decrease the amount of the drug subsequently administered.

Prometheus sued Mayo for infringement of the two patents. Mayo filed a motion for summary judgment to declare the patents invalid for improperly claiming natural laws. On appeal, the Supreme Court held that the patents were invalid because "the steps in the claimed processes (apart from the natural laws themselves) involve well-understood, routine, conventional activity previously engaged in by researchers in the field."

Legal Background

The United States Patent Act, §101, defines patent-eligible subject matter to include "any new and useful process", but the Court has long recognized that §101 impliedly excludes natural laws, physical phenomena and abstract idea. This being said, all inventions rely to some extent on natural laws, and so a process is not patent-ineligible merely because it recites a natural law. The difficulty is in determining whether a process claim effectively seeks patent protection for the natural law itself, especially when the process is not tied to a particular machine or apparatus. Prior to Prometheus, a series of Supreme Court decisions2 provided guideposts for assessing patent-eligibility, as follows:

  • the patentee cannot evade the exclusionary principle by either simply limiting the use of a natural law to a particular technological environment, or adding an insignificant step to the application of the natural law;
  • the transformation and reduction of an article to a different state or thing is a clue to the patentability of a process claim that does not include a particular machine, but satisfying this "machine-or-transformation test" is not a necessary requirement;
  • when assessing the patent-eligibility of a process claim, the steps of a claim must be considered as a whole, and the novelty of the steps either in isolation or in combination is not relevant.

The Court's Decision

In Prometheus, the Court characterized the precise relationship between the metabolite concentration and the effectiveness or toxicity of the thiopurine drug to be a natural law. This was because the relationship existed independently from any human action. Proceeding on this basis, the Court considered the discrete issue to be whether the process claims "add enough to their statement of the correlations to allow the processes they describe to qualify as patent-eligible processes that apply natural laws."

To address this issue, the Court analyzed the steps of the process claim, both in isolation and in combination. With respect to the "administering step", the Court stated "doctors used thiopurine drugs to treat patients suffering from autoimmune disorders long before anyone asserted these claims". With respect to the "wherein step", the Court stated that it simply informed doctors about the relevant natural law, while trusting doctors to use those laws appropriately where they are relevant to their decision making. With respect to the "determining step", the Court stated that "methods for determining metabolite levels were well known in the art". With respect to the steps viewed as a whole, the Court stated that the steps "add nothing significant beyond the sum of their parts taken separately." Accordingly, the Court concluded that the claims were patent-ineligible.


For inventors and other parties interested in seeking or challenging patent protection in the United States for process claims, particularly for medical diagnostic tests, the Prometheus decision provides the additional guideposts for assessing patent-eligibility, as follows:

  • patent-eligibility is the threshold issue for patent validity, that precedes issues of novelty, obviousness and adequacy of the specification;
  • in a departure from the Court's past statements, it is permissible to consider the novelty or obviousness of the claimed steps, both in isolation and in combination, when determining patent-eligibility;
  • the exclusionary principle is less likely avoided when a process claim simply adds conventional steps at a high level of generality to natural laws in the abstract, than when a process claims includes unconventional steps that achieve a specific useful result in a unitary manner;
  • the machine-or-transformation test is neither a sufficient nor necessary criterion for patent-eligibility.

The full impact of the U.S. Supreme Court's decision in Prometheus will only be appreciated as trends in its application emerge by the lower courts against patent documents with process claims that recite natural laws not tied to a particular machine or apparatus.

In the absence of a positively stated test, considerable uncertainty may continue to surround the patent eligibility of such process claims. It would seem, however, that the Prometheus decision tends to narrow the threshold of patent-eligibility. Indeed, a lower court relied on the Prometheus decision only 10 days after it was released to invalidate a patent relating to a system, method and computer program for guiding the selection of therapeutic treatment regimens for complex disorders.3

At the very least, the Prometheus decision suggests the need for a fresh consideration of the patent-eligibility of these types of process claims.


1 U.S. Patent No. 6,355,623 and U.S. Patent No. 6,680,302.

2 See: Gottschalk v. Benson, 409 U.S. 63 (1972); Parker v. Flook, 437 U.S. 584 (1978); Diamond v. Diehr, 450 U.S. 175 (1981); and Bilski v. Kappos, 561 US __, (2010).

3 Smartgene Inc. v. Advanced Biological Laboratories, SA (D.D.C 2012).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Peter S.L. Wong
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.